Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ta-Ming Liu

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Epigenomics|June 8, 2010
Methods in DNA methylation profilingTao Zuo, Benjamin Tycko, Ta-Ming Liu, et al.
Carcinogenesis|February 10, 2011
Estrogen-mediated epigenetic repression of the imprinted gene cyclin-dependent kinase inhibitor 1C in breast cancer cellsBenjamin A T Rodriguez, Yu-I Weng, Ta-Ming Liu, et al.
Blood|May 15, 2015
Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activationTa-Ming Liu, Jennifer A Woyach, Yiming Zhong, et al.
Cancer Research|January 11, 2011
Epigenetic silencing mediated through activated PI3K/AKT signaling in breast cancerTao Zuo, Ta-Ming Liu, Xun Lan, et al.
Blood|October 9, 2014
OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cellsTa-Ming Liu, Yonghua Ling, Jennifer A Woyach, et al.
The New England Journal of Medicine|May 30, 2014
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinibJennifer A Woyach, Richard R Furman, Ta-Ming Liu, et al.
Blood|July 27, 2013
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytesJason A Dubovsky, Kyle A Beckwith, Gayathri Natarajan, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Epigenomics|June 8, 2010
Methods in DNA methylation profilingTao Zuo, Benjamin Tycko, Ta-Ming Liu, et al.
Carcinogenesis|February 10, 2011
Estrogen-mediated epigenetic repression of the imprinted gene cyclin-dependent kinase inhibitor 1C in breast cancer cellsBenjamin A T Rodriguez, Yu-I Weng, Ta-Ming Liu, et al.
Blood|May 15, 2015
Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activationTa-Ming Liu, Jennifer A Woyach, Yiming Zhong, et al.
Cancer Research|January 11, 2011
Epigenetic silencing mediated through activated PI3K/AKT signaling in breast cancerTao Zuo, Ta-Ming Liu, Xun Lan, et al.
Blood|October 9, 2014
OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cellsTa-Ming Liu, Yonghua Ling, Jennifer A Woyach, et al.
The New England Journal of Medicine|May 30, 2014
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinibJennifer A Woyach, Richard R Furman, Ta-Ming Liu, et al.
Blood|July 27, 2013
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytesJason A Dubovsky, Kyle A Beckwith, Gayathri Natarajan, et al.
Pageof 1